Andrew Perry - 03 Jan 2022 Form 4 Insider Report for G1 Therapeutics, Inc.

Role: Chief Commercial Officer
Signature: /s/ James Stillman Hanson, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 03 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 05 Jan 2022, 19:25:31 UTC
Previous filing: 17 Aug 2021
Next filing: 05 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GTHX	Common Stock	Award	$0	+6,000	+30000%	$0.000000	6,020	03 Jan 2022	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GTHX	Stock Options (Right to buy)	Award	$0	+26,500		$0.000000	26,500	03 Jan 2022	Common Stock	26,500	$10.69	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2023 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F2	Each RSU represents a contingent right to receive one share of Issuer common stock.
F3	Represents (i) 20 shares of common stock; and (ii) 6,000 RSUs from award granted on January 3, 2022.
F4	The shares underlying this option vest as to 25% of the shares on January 3, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.